CoChat
Sign Up
Cited by 86

The DOI matches its Crossref record.

Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: A randomized double-blind study

Mabuchi, Hiroshi, Nohara, Atsushi, Kobayashi, Junji, Kawashiri, Masa-aki, Katsuda, Shoji, Inazu, Akihiro, Koizumi, Junji·2007·Atherosclerosis
DOI 10.1016/j.atherosclerosis.2007.06.010
Open this paper in CoChat — free account

Abstract

The long-term efficacy and safety of HMG-CoA reductase inhibitors (statins) have been established in large multicenter trials. Inhibition of this enzyme, however, results in decreased synthesis of cholesterol and other products downstream of mevalonate, such as CoQ10 or dolichol. This was a randomized double-blind, placebo-controlled study that examined the effects of CoQ10 and placebo in hypercholesterolemic patients treated by atorvastatin. Eligible patients were given 10mg/day of atorvastatin for 16 weeks. Half of the patients (n=24) were supplemented with 100mg/day of CoQ10, while the other half (n=25) were given the placebo. Serum LDL-C levels in the CoQ10 group decreased by 43%, while in the placebo group by 49%. The HDL-C increment was more striking in the CoQ10 group than in the placebo group. All patients showed definite reductions of plasma CoQ10 levels in the placebo group, by 42%. All patients supplemented with CoQ10 showed striking increases in plasma CoQ10 by 127%. In conclusion atorvastatin definitely decreased plasma CoQ10 levels and supplementation with CoQ10 increased their levels. These changes in plasma CoQ10 levels showed no relation to the changes in serum AST, ALT and CK levels. Further studies are needed, however, for the evaluation of CoQ10 supplementation in statin therapy.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.atherosclerosis.2007.06.010

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 27

  1. Stamler, 1986, Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT), JAMA, 256, 2823, 10.1001/jama.256.20.2823 · DOI · Paper page
  2. Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia., N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001 · DOI · Paper page
  3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;334:1383-9.
  4. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002;106:1024-8. · DOI · Paper page
  5. Kontush, 1997, Plasma ubiquinol-10 is decreased in patients with hyperlipidaemia, Atherosclerosis, 129, 119, 10.1016/S0021-9150(96)06021-2 · DOI
  6. Steinberg, 1989, Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity, N Engl J Med, 320, 915
  7. Mabuchi, 2005, Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients, J Atheroscler Thromb, 12, 111, 10.5551/jat.12.111 · DOI
  8. Noji, 2002, Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia, Atherosclerosis, 163, 157, 10.1016/S0021-9150(01)00765-1 · DOI
  9. Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499 · DOI · Paper page
  10. Kotani, 1994, Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum, Biochim Biophys Acta, 1215, 121, 10.1016/0005-2760(94)90100-7 · DOI
  11. Abe, 1989, Alterations in fructosamine and glycated albumin levels during childhood, Ann Clin Biochem, 26, 328, 10.1177/000456328902600405 · DOI
  12. Yamashita, 1997, Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress, Anal Biochem, 250, 66, 10.1006/abio.1997.2187 · DOI
  13. Langsjoen, 2003, The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10, A review of animal and human publications, BioFactors, 18, 101, 10.1002/biof.5520180212 · DOI · Paper page
  14. Jamal, 2004, Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme. A reductase inhibitors, Am Heart J., 147, 956, 10.1016/j.ahj.2003.12.037 · DOI
  15. Okamoto, 1986, Serum levels of coenzyme Q10 and lipids in patients during total parenteral nutrition, J Nutr Sci Vitaminol (Tokyo), 32, 1, 10.3177/jnsv.32.1 · DOI
  16. Mabuchi, 2007, Coenzyme Q10 reduction with statins: another pleiotropic effect, Curr Drug Ther, 2, 39, 10.2174/157488507779422338 · DOI
  17. Laaksonen, 1995, Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans, Clin Pharmacol Ther, 57, 62, 10.1016/0009-9236(95)90266-X · DOI · Paper page
  18. Laaksonen, 1996, The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle, Am J Cardiol, 77, 851, 10.1016/S0002-9149(97)89180-1 · DOI · Paper page
  19. Bliznakov, 2002, Lipid-lowering drugs (statins), cholesterol, and coenzyme Q10. The Baycol case—modern Pandora's box, Biomed Pharmacother, 56, 56, 10.1016/S0753-3322(01)00150-0 · DOI
  20. Flint, 1997, Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro, Toxicol Appl Pharmacol, 145, 91, 10.1006/taap.1997.8131 · DOI
  21. MacDonald, 1988, Preclinical evaluation of lovastatin, Am J Cardiol, 62, 16J, 10.1016/0002-9149(88)90003-3 · DOI
  22. Singh, 2003, Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction, Mol Cell Biochem, 246, 75, 10.1023/A:1023408031111 · DOI
  23. Bargossi, 1994, Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors, Mol Aspects Med, 15, s187, 10.1016/0098-2997(94)90028-0 · DOI
  24. Bleske, 2001, The effect of pravastatin and atorvastatin on coenzyme Q10, Am Heart J, 142, E2, 10.1067/mhj.2001.116762 · DOI
  25. Schaefer, 2004, Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats, Toxicol Appl Pharmacol, 194, 10, 10.1016/j.taap.2003.08.013 · DOI
  26. Stocker, 2006, Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: a prospective case-control study from the LIPID study, Atherosclerosis, 187, 198, 10.1016/j.atherosclerosis.2005.09.004 · DOI
  27. Caso, 2007, Effect of coenzyme q10 on myopathic symptoms in patients treated with statins, Am J Cardiol, 99, 1409, 10.1016/j.amjcard.2006.12.063 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Mabuchi, H., Nohara, A., Kobayashi, J., Kawashiri, M.-A., Katsuda, S., Inazu, A., & Koizumi, J.
Venue
Atherosclerosis
Publisher
Elsevier BV
Published
2007-12
Volume
195
Issue
2
Pages
e182-e189
ISSN
0021-9150
DOI
10.1016/j.atherosclerosis.2007.06.010
Cited by
86
References
0
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review